Forum 2026 Vorwort

entwickeln, um neue Therapien zu erforschen. Die Fortschritte in Bereichen wie 3D Zell- und Organoidkultur, ADCs, CRISPR, PROTACs, Next Generation Sequencing, hochauflösende Mikroskopie sowie weitere neue Technologien erweitern die Möglichkeiten der...

Energy transfer as a general approach to assess target occupancy and residence time for kinase inhibitors and PROTACs in living cells

Matt Robers, Promega We will describe the application of an energy transfer technique (NanoBRET) that enables the first live cell approach to broadly profile compound fractional occupancy and residence time against a variety of target classes including...

Enabling effective data management for PROTAC development

Emilia Hietala, CCD Vault, UK PROteolysis TArgeting Chimeras (PROTACs) are chimeric molecules to induce the multistep degradation process of a protein of interest through the ubiquitin proteasomal system (UPS). Despite PROTACs are from rising interest...

Measurement of PROTAC ternary complex formation using the switchSENSE® Y-structure and FRET signals

Ralf Strasser, Dynamic Biosensors, München Proteolysis targeting chimeras (PROTACs) are essential bifunctional small molecules that engage the formation of a ternary complex consisting of an E3 ubiquitin ligase, a target protein of interest and the...

Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization

Martin Schwalm, Inst. F. Biochemie, Uni Frankfurt PROteolysis TArgeting Chimeras (PROTACs) are chimeric molecules to induce the multistep degradation process of a protein of interest through the ubiquitin proteasomal system (UPS). Despite PROTACs are...

Clues to Molecular Glues

the drug development community. However, the identification molecular glues and the optimization of bifunctional degraders (PROTACs) is far from trivial. Here, I will present the development of the first FKBP51 PROTACs and the discovery of the first...

Targeted protein degradation & protein proximity – a journey from high throughput screening to developing drugs for the ‘undruggable’ proteome

targetable). After providing a broader overview of the TPD & PPI fields, the talk will focus on molecular glues and PROTACs (Proteolysis targeting chimerics) with an emphasis on high throughput screening and subsequent lead identification approaches....

2026

Proteomics for target and pathway deconvolution

identification and deconvolution for specific compound classes, such as kinase or HDAC inhibitors or protein degraders (PROTACs, IMiDs and alikes), as well as generic target-class agnostic approaches.

Licence to eliminate- Protein degraders @ Merck

libraries for the identification and characterization of new degraders and the optimization of our early bifunctional PROTACs to effective eliminators of drug targets.

Deconvoluting the Drivers of Targeted Protein Degradation

new therapeutic strategy consisting of small molecules, most commonly molecular glues or Proteolysis Targeting Chimeras (PROTACs), which elicit degradation of a target protein. Significant challenges persist to characterize the cellular mechanism of...

Deep proteomic screening for systematic discovery of degrader targets and mechanisms

degrader drugs that reprogram E3 ligases come mainly in two varieties: heterobifunctional molecules also known as PROTACs (PROteolysis TArgeting Chimeras) or molecular glue compounds. Systematic discovery of novel molecular glues and their cellular...

PRISKA: Integrated screening- and knowledge-platform for molecular degrader

screening analysis and refinement through different algorithms. Among them a knowledge graph that maps TPD actors (PROTACs, MGs, etc.), annotated through links to other public chemical biology data, as well as chemoinformatics tools aimed at identifying...